Zhejiang Xinguang Pharmaceutical Co., Ltd.

Equities

300519

CNE1000027T3

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 10/05/2024 am IST 5-day change 1st Jan Change
13.03 CNY -3.34% Intraday chart for Zhejiang Xinguang Pharmaceutical Co., Ltd. +2.36% -21.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves the Cash Dividend for 2022, Payment on 30 May 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes Profit Distribution for 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Xinguang Pharmaceutical Expects Q3 Profit to Tumble By Up to 10% MT
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Profit Distribution for 2021, Payable on 26 May 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes Final Dividend for 2021 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2020, Payable on May 28, 2021 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes the Final Cash Dividend for 2020 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Cash Dividend on A Shares for the Year 2019, Payable on 27 May 2020 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Chart Zhejiang Xinguang Pharmaceutical Co., Ltd.
More charts
Zhejiang Xinguang Pharmaceutical Co Ltd is a China-based company mainly engaged in development, manufacture and sales of Chinese patent medicines, chemical medicines and health foods. The main products of the Company are cardiovascular and cerebrovascular diseases medicine as well as traumatic disease medicine. Its other products include the drugs used in respiratory systems, digestive systems, urinary systems, paediatric diseases and immune systems. The Company operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300519 Stock
  4. News Zhejiang Xinguang Pharmaceutical Co., Ltd.
  5. Zhejiang Xinguang Pharmaceutical Expects Q3 Profit to Tumble By Up to 10%
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW